As of 2024-12-04, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (26.40) USD. This relative valuation is based on P/E multiples. With the latest stock price at 253.07 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -110.4%.
The range of the Relative Valuation is (19.22) - (33.59) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 13.0x | 10.2x |
| Forward P/E multiples | 7.5x - 13.0x | 10.2x |
| Fair Price | (19.22) - (33.59) | (26.40) |
| Upside | -107.6% - -113.3% | -110.4% |
| Date | P/E |
| 2024-11-26 | -97.19 |
| 2024-11-25 | -97.43 |
| 2024-11-22 | -95.06 |
| 2024-11-21 | -95.80 |
| 2024-11-20 | -96.58 |
| 2024-11-19 | -90.94 |
| 2024-11-18 | -90.16 |
| 2024-11-15 | -91.44 |
| 2024-11-14 | -100.12 |
| 2024-11-13 | -102.71 |
| 2024-11-12 | -104.40 |
| 2024-11-11 | -108.62 |
| 2024-11-08 | -107.69 |
| 2024-11-07 | -105.67 |
| 2024-11-06 | -105.98 |
| 2024-11-05 | -102.98 |
| 2024-11-04 | -104.79 |
| 2024-11-01 | -106.33 |
| 2024-10-31 | -103.49 |
| 2024-10-30 | -109.27 |
| 2024-10-29 | -110.51 |
| 2024-10-28 | -111.37 |
| 2024-10-25 | -110.58 |
| 2024-10-24 | -114.01 |
| 2024-10-23 | -114.46 |
| 2024-10-22 | -115.09 |
| 2024-10-21 | -113.35 |
| 2024-10-18 | -114.88 |
| 2024-10-17 | -115.19 |
| 2024-10-16 | -116.67 |
| 2024-10-15 | -111.55 |
| 2024-10-14 | -109.98 |
| 2024-10-11 | -110.37 |
| 2024-10-10 | -108.16 |
| 2024-10-09 | -105.16 |
| 2024-10-08 | -105.27 |
| 2024-10-07 | -103.56 |
| 2024-10-04 | -104.03 |
| 2024-10-03 | -104.63 |
| 2024-10-02 | -105.41 |
| 2024-10-01 | -107.16 |
| 2024-09-30 | -106.76 |
| 2024-09-27 | -106.72 |
| 2024-09-26 | -106.58 |
| 2024-09-25 | -105.87 |
| 2024-09-24 | -105.20 |
| 2024-09-23 | -105.52 |
| 2024-09-20 | -106.32 |
| 2024-09-19 | -107.27 |
| 2024-09-18 | -106.03 |